Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A proliferation-inducing ligand receptors refers to the cell surface receptors that bind APRIL (A Proliferation-Inducing Ligand), a member of the tumor necrosis factor (TNF) superfamily. The main receptors for APRIL are TACI (Transmembrane Activator and CAML Interactor, also known as TNFRSF13B) and BCMA (B-cell Maturation Antigen, also known as TNFRSF17). These receptors play crucial roles in B cell biology, regulating plasma cell survival, immunoglobulin class switching, and activated B cell function. Dysregulation of this pathway is implicated in autoimmune diseases, IgA nephropathy, and certain cancers, making it a therapeutic target.
APRIL binding triggers downstream signaling pathways (NF-kB, MAPK, PI3K/Akt) that promote cell survival, proliferation, and immunoglobulin class switching.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on A Proliferation-Inducing Ligand Receptors (APRIL Receptors).